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Yield Optimisation of Hepatitis 
B Virus Core Particles in E. coli 
Expression System for Drug 
Delivery Applications
Izzat Fahimuddin Bin Mohamed Suffian1, Mitla Garcia-Maya2, Paul Brown2, Tam Bui3, 
Yuya Nishimura4, Amir Rafiq Bin Mohammad Johari Palermo5, Chiaki Ogino4, Akihiko Kondo4 
& Khuloud T. Al-Jamal1
An E. coli expression system offers a mean for rapid, high yield and economical production of Hepatitis 
B Virus core (HBc) particles. However, high-level production of HBc particles in bacteria is demanding 
and optimisation of HBc particle yield from E. coli is required to improve laboratory-scale productivity 
for further drug delivery applications. Production steps involve bacterial culture, protein isolation, 
denaturation, purification and finally protein assembly. In this study, we describe a modified E. coli  
based method for purifying HBc particles and compare the results with those obtained using a 
conventional purification method. HBc particle morphology was confirmed by Atomic Force Microscopy 
(AFM). Protein specificity and secondary structure were confirmed by Western Blot and Circular 
Dichroism (CD), respectively. The modified method produced ~3-fold higher yield and greater purity 
of wild type HBc particles than the conventional method. Our results demonstrated that the modified 
method produce a better yield and purity of HBc particles in an E. coli-expression system, which are fully 
characterised and suitable to be used for drug delivery applications.
The past quarter century has brought biomedical and health sciences researchers to focus on nanotechnologies. 
Cross-disciplinary research bringing together engineering, biology, physics and chemistry resulted in the pro-
duction of a vast and diverse number of nanovectors, which have been explored in drug delivery and imaging1. In 
nanotechnology, 1–100 nm diameter particles are referred to as nanoparticles. Cancer-related nano-technology 
studies have shown substantial development in producing nanoparticles with different sizes, chemical nature 
and structure, all of which influence their applications including administration for targeted therapeutic and 
imaging moieties2,3. Nanoparticles can be developed from different materials: organic, inorganic or biological 
(macro) molecules. The latter, referred to as bio-nanoparticles can be formed by assembly of protein subunits4. 
One popular example is ferritin, a naturally occurring human protein, which is able to self-assemble into spheri-
cal capsids or cages5. However, the most promising protein cages are considered to be virus-derived nanoparticles 
or virus-like particles (VLPs). VLPs are self-assembling, non-replicative and non-pathogenic particles, which 
structurally mimic the viral capsid lacking the viral genome6. They can either be isolated directly after the coat 
protein expression in eukaryotic cells, or assembled in vitro from coat protein subunits purified from any recom-
binant host; ranging from mammalian cells to bacteria7,8.
As the first VLP candidate and the first icosahedral VLP carriers, HBc particles remain the most flexible and 
promising model for knowledge-based display of foreign peptide sequences9,10. HBc particles are hollow nano-
particles ranging from 30 to 34 nm in diameter with 7 nm thick envelopes11. These core particles are icosahedral 
nucleocapsids with primarily triangulation number T = 3 or T = 4 symmetry, each containing 180–240 units of 
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21 kDa core monomers12. Their self-assembly property and ability to assemble and dis-assemble freely through 
altering the urea concentration, modifying salt concentration and reducing disulfide bonds13–15, have been uti-
lised to allow for encapsulation of various drugs16 and other biomolecules including nuclease17, oligonucleotides18 
and siRNA19.
HBc particles can be expressed in homologous and heterologous expression systems. Escherichia coli offers 
a means for rapid, high yield and economical production of recombinant proteins20,21. However, high-level pro-
duction of recombinant bio-nanoparticles in bacteria on a laboratory-scale is challenging. Challenges include: (1) 
biomass production of specific-gene selection cells22, (2) degradation of protein by host cell proteases23, (3) pro-
tein isolation from inclusion bodies24 and (4) successful protein folding25. Therefore, a yield optimisation study 
of HBc particles expression in E. coli is required to improve the productivity of the laboratory-scale for further 
drug delivery applications.
This study focused on developing an improved method (I) for producing wild type HBc (WT-HBc) particles 
in high yields, suitable for drug delivery applications. For comparison, WT-HBc particles were also prepared 
by the “conventional” method (C) reported previously by others26, Production steps involve bacterial culture, 
protein isolation, denaturation, purification and finally VLP assembly. The protein yield and purity were deter-
mined by Nanodrop™ . HBc particle morphology was confirmed by Atomic Force Microscopy (AFM). Protein 
specificity and secondary structure were confirmed by Western Blot and Circular Dichroism (CD), respectively. 
We concluded that the modified method produced ~3 fold higher yield and greater purity of HBc particles than 
the conventional method.
Results
Optimisation of the WT-HBc particles expression and assembly method.  In this study, we aimed 
at developing an improved method (I) for producing wild type HBc (WT-HBc) particles in high yields, suita-
ble for drug delivery applications. For comparison, WT-HBc particles were also prepared by the “conventional” 
method (C) reported previously by others26. The four steps involved including bacterial culture, protein isolation, 
denaturing and assembly are summarised in Fig. 1. The major differences between the two methods and the 
rationale for these modifications will be highlighted here.
E. coli was chosen as the host organism to produce HBc particles on a laboratory scale, due to the advan-
tages of relatively simple fermentation design and high final cell densities20. Auto-Induction Media Terrific Broth 
(AIM-TB) was used in the new method to replace Luria-Bertani Broth (LB) used previously. AIM-TB supports 
E. coli growth to a cell density 10-fold or higher in a shake flask26,27.
Figure 1. A scheme summarising WT-HBc particles production in E. coli expression system. WT-HBc 
particles were prepared using one of the two methods; the “conventional” or “improved” method.
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A protease inhibitor and RNase were included in the lysis buffer of the new method (Fig. 1), specifically to 
protect HBc proteins from cleavage by endogenous proteases and to remove contaminating RNA28,29.
Urea is used as a denaturing agent to solubilise the inclusion bodies containing WT-HBc particles. In the “con-
ventional” method, a moderate urea concentration (4 M) in dissociation buffer was used compared to 8 M used 
in the new method. The higher urea concentration was expected to denature HBc particles to monomers more 
efficiently13. The His-tag, located at the C-terminus of HBc protein, resides inside the fully assembled particles30,31, 
so efficient denaturing of the HBc particles makes the His-tag more available for His-tag affinity chromatography, 
used in a later step of purification.
Purified WT-HBc protein, in the monomer form, was then re-folded via the assembly step to restore the core 
particles structure. In the “conventional” method, after affinity chromatography urea was removed by dialysis 
against Tris/EDTA/NaCl assembly buffer, where pronounced precipitation was associated with the sudden drop 
in urea concentration. In the new method; the purified WT-HBc monomers were re-folded by a stepwise reduc-
tion in urea concentration first to 2 M during column elution then to 0.5 M in dialysis against assembly buffer 
(DTT/EDTA/Tris/NaCl/CaCl2) then dialysis against buffer containing no urea. This altered assembly strategy 
was designed to improve the efficiency of protein re-assembly by reducing random protein folding, induced by 
disulfide bonds formation32,33, thereby increasing the yield of appropriately assembled WT-HBc particles.
Protein yield, particle morphology and size. Significantly higher protein yields (p < 0.001) from 1 l 
growth medium, were obtained for WT-HBc prepared using the new method (3.21 ± 0.21 mg) compared with 
the conventional method (1.21 ± 0.30 mg) (Table 1). Height AFM images of HBc prepared by both methods 
revealed relatively monodisperse and spherical structures, observed only in case of the assembled particles. The 
“halo” observed suggested the presence of core-shell type structures. HBc mean diameters measured by AFM 
were 36.61 ± 8.51 nm and 33.77 ± 4.58 nm (p = 0.45 (> 0.05)), respectively (Fig. 2). The OD260/OD280 values, used 
to determine the purity of the protein from nucleic acids contamination, are shown in Table 1. WT-HBc (I) 
showed a significantly lower value of OD260/OD280 ratio (0.58 ± 0.01) than WT-HBc (C) (1.02 ± 0.04) suggesting 
the higher nucleic acid contamination in the latter. A OD260/OD280 ratio greater than 0.6 indicates nucleic acid 
contamination in the protein samples34. In addition, as shown in Fig. 3 (cropped gels) and Supplementary Inform
ation Figure S1 (full length gels), some unknown protein bands were observed on SDS-PAGE at molecular weight 
lower than 20 kDa, in case of WT-HBc (C) (Fig. 3A, Supplementary Figure S1a), but not for WT-HBc (I) (Fig. 3B, 
Supplementary Figure S1b). This result confirmed the impurities observed in the WT-HBc (C) samples. Overall, 
these results indicated that the new method provides HBc particles of an improved yield and purity.
Protein specificity and secondary structure analysis of the purified WT-HBc particles.  Western 
blot analysis was performed to confirm the protein specificity of WT-HBc particles. The presence of HBc antigen 
and His-tag, as biochemical markers, was confirmed. Specific protein bands, positive for anti-6-His and anti-HBc 
antibodies, were observed at 21 kDa26 (Fig. 4A (cropped blot), Supplementary Information Figure S2 (full length 
blots)) confirming the successful expression of WT-HBc particles by both methods.
The typical secondary structure of the WT-HBc35 monomer was confirmed by far-UV circular dichro-
ism (CD). WT-HBc particles from both preparations displayed a predominantly α -helix conformation with 
well-defined characteristic negative bands at 208 and 222 nm35 (Fig. 4B).
Discussion
HBc particles have been expressed extensively in several types of hosts including E. coli36. However, it has been a 
challenge to produce a high yield of purified HBc particles on a laboratory-scale. In the conventional method of 
HBc particles production in E. coli, LB media is used as a culture medium37. LB media can support E. coli growth 
at an OD600 0.7–0.8 under normal shaking incubation conditions38. However due to its mid-exponential growth 
phase, the pH of the cultures drops to pH 4 to 5 upon saturation, causing the antibiotics such as ampicillin to be 
degraded, resulting in a partial or no selection of cells. Under these conditions, 80% of the total cell population 
may not contain the intended plasmid, preventing these cells from being induced to express the target protein, 
resulting in low protein yields23. One approach to overcome this problem is to use an auto-induction media such 
as the AIM-TB media39. Auto-induction is based on the function of lac operon regulatory elements using a mix-
ture of glucose, glycerol and lactose under diauxic growth conditions. During the initial growth period, glucose 
is preferentially used as a carbon source as a first sugar source. As the glucose is depleted, usually in mid to late 
log phase, the second source of sugar, lactose is taken up and converted by β -galactosidase to the inducer allol-
actose. Allolactose causes the release of lac repressor from its specific binding sites in the DNA, which induces 
the expressions of T7 RNA polymerase from the lacUV5 promoter, which thereby unblocks T7lac promoters, 
allowing expression of the target protein by T7 RNA polymerase. This transition from the un-induced to induced 
Method HBc code Protein yield (mg)[1],[2] OD260:OD280[1],[2]
Conventional WT-HBc (C) 1.21 ± 0.3 1.02 ± 0.04
Improved WT-HBc (I) 3.21 ± 0.21*** 0.58 ± 0.01***
Table 1.  Yield and nucleic acid contamination characterisation of HBc particles prepared using 
“Conventional” or “Improved” methods. [1] Values were obtained with Nanodrop from 1 litre bacteria 
containing media normalised to LB media. [2] Results are expressed an average ± SD (n = 3). ***p = 0.00024  
(< 0.001) (One-way ANOVA).
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state under metabolic control of the expression host is one of the factors contributed to the higher amount of pro-
tein expressed in the bacteria. Furthermore, the increased richness of the AIM-TB media endorse to the higher 
amount of lysate harvested23.
Inclusions of protease inhibitors and RNase in a lysis buffer might be the important parameters for HBc isola-
tion from the E. coli lysate. Bacterial cells contain many different types of proteases. As soon as cells are disrupted, 
proteases are released and can quickly degrade any protein, causing a drastic reduction in the protein yield during 
Figure 2. Morphological analysis of purified HBc core particles with Atomic Force Microscopy (AFM).  
(A) AFM images using tapping mode AFM (TM-AFM) and (B) Histogram analysis of assembled HBc particles. 
HBc particles were deposited on the mica substrates and measurements were carried out in air at 25 °C, using 
a Bruker Dimension ICON with Scan Assist. Dis-assembled HBc were achieved by dilution in distilled water 
at 40 °C for 10 min. Core shell structure was observed for the assembled particles for both formulations. 
Histograms were obtained for n = 50, analysed using WSxM v5.0 Developed 6.2 and Origin 7.5 software. Scan 
size is 300 nm × 300 nm. Scale bars are 60 nm.
Figure 3. Elution profile of WT-HBc monomers from Ni2+-chelate affinity chromatography column 
(cropped gels). A column with 6 ml of cOmplete™ His-Tag Purification Resin was equilibrated with 3-times 
bed-volume (18 ml) of the dissociation buffer. The column was loaded with the protein probe and washed with 
18 ml dissociation buffer. Bound proteins were eluted with 14 ml of elution buffer and collected in 1 ml fractions. 
The aliquots of each fractions were subjected to SDS-PAGE gel electrophoresis and stained with Coomassie 
Brilliant Blue. M, marker in kDa; Numbers 1–14 represent aliquots of the respective elution fractions for (A) 
WT-HBc (C) or (B) WT-HBc (I) monomers. Blue arrows represent WT-HBc monomers (21 kDa). Higher 
number of fractions (7 fractions, lane 2–8) were collected in case of WT-HBc (I) compared to WT-HBc (C)  
(5 fractions, lane 4–8). Some unknown protein bands were observed at molecular weight lower than 20 kDa  
(red arrow).
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isolation and purification. Therefore, inclusion of protease inhibitors in the new method prevents their proteo-
lytic activity which can cause cleavage of HBc protein fractions28. HBc particles can be contaminated with the 
host RNA when expressed in an E. coli expression system40. Addition of RNase in the early stage of purification 
removes contaminating RNA, hence preventing any remnant non sequitur activity for further studies29.
In this study, we isolated WT-HBc particles from protein inclusion bodies, which are insoluble protein aggre-
gates, that can be easily separated by centrifugation from the rest of the soluble bacterial cytoplasmic proteins41. 
In order to solubilise the inclusion bodies, the extraction of protein is generally performed in the presence of 
denaturing agents. Here, a strategy of urea usage has been chosen for its compatibility with protein folding and 
most chromatographic procedures42,43. In the “conventional” method, a moderate urea concentration (4 M) in 
dissociation buffer was only able to solubilise the protein inclusion bodies partially with undissolved material 
observed after overnight incubation. However, in the new method, with 8 M urea in the dissociation buffer, the 
protein inclusion bodies were completely solubilised and dissociated WT-HBc proteins. A high concentration of 
urea acts to enhance the aqueous solubility of protein by weakening the hydrophobic interactions and stabilising 
the solvation of the unfolded protein. This allows a greater number of non-polar side chains to be exposed to 
water molecules, thus resulting in a completely solubilised protein in solution44,45.
The abrupt removal of urea to re-fold HBc monomers by dialysis against Tris/EDTA/NaCl assembly buffer 
led to precipitation, most probably due to the random proteins re-folding, which may have resulted in a low yield 
of the purified assembled WT-HBc particles. Here, a strategy of adding a reducing agent, DTT and a divalent 
salt, CaCl2 was used in the new method, helping to reduce the protein aggregation problem. DTT, a thiol reagent 
was used to reduce the disulfide bonds of proteins, which helps to prevent intra-molecular and intermolecular 
disulfide bonds from forming between cysteine residues of the protein. Ca2+ ion can also promote HBc parti-
cles assembly. It is suggested that the ionic strength from the calcium ions increases the electrostatic attractions 
between the proteins monomers thus act as an electrostatic switch for the protein self-assembly46. So when a 
highly concentrated WT-HBc monomers solution was dialysed under these conditions, the proteins re-folded at 
the correct geometry bonding, stabilising the protein structure, resulting in high re-folding yield of HBc particles 
and fewer aggregation problems16,47,48.
Another study by Zlotnick et al. demonstrated that the usage of assembly effectors could enhance HBc 
particles assembly. The usage of HAP1 [methyl 4-(2-chloro-4-fluorophenyl)-6-methyl-2-(pyridin-2-yl)- 
1,4-dihydropyrimidine-5-carboxylate], a type of heteroaryldihydropyrimidine molecules, together with 150 mM 
NaCl was found to accelerate HBc particles assembly kinetics, resulting in 65% particles assembly, compared with 
particles assembled in 150 mM NaCl only (25% assembly)49,50. The addition of assembly effector in the future 
might be a good approach to improve protein assembly yield of HBc particles.
Figure 4. Protein specificity and secondary structure analysis of HBc particles. (A) Western blotting 
(cropped blot) and (B) Circular Dichroism (CD) analysis of WT-HBc particles. Denatured HBc samples were 
subjected to SDS-PAGE followed by immuno-blotting using anti-6-His and anti-HBc antibodies. Results 
confirmed the presence of specific protein bands at 21 kDa. CD graph shows the overall conformation of far-UV 
CD analysis of WT-HBc core particles. WT-HBc (C) (solid line) and WT-HBc (I) (dashed line) exhibited 
spectra typical of α -helix-containing proteins with minima at 220 and 208 nm. The CD spectra are typical of 
WT-HBc core monomer secondary structure.
www.nature.com/scientificreports/
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The organisation of HBc particles is known to be largely α -helical and quite different from previously known 
viral capsid proteins with β -sheet jellyroll packings51,52. Association of two amphipathic α -helical hairpins results 
in the formation of a dimer with a four-helix bundle as the major central feature. The four-helix bundles protrude, 
forming spikes, presents as a central part of major immudominant region of the HBc particles53. Here, both 
WT-HBc particles exhibited typical spectra of α -helix-containing proteins structure.
Conclusion
The experimental work has focused on the initial development of functional nano-assemblies of virus-like par-
ticles for therapeutic applications in addition to the development of “proposed” novel biocompatible and thera-
peutically efficient nanocarriers for cancer. We demonstrated an improved method to produce a better yield and 
purity of HBc particles in an E. coli-expression system. The HBc particles produced are fully characterised and are 
suitable to be used to encapsulate drugs/biomolecules or to be bioengineered with targeting molecules.
Materials
Luria-Bertani-Broth Miller, tryptone, yeast extract powder, MOPS, ampicillin sodium, IPTG dioxan free, 
AIM-terrific broth base including trace elements, Tris base Ultra-Pure, EDTA disodium and dithiothreitol 
(DTT) were obtained from ForMedium™ (UK). Urea (carbamide) were obtained from Melford (UK). Imidazole, 
Glycerol, 2-mercapoethanol, N, N, N’, N’-tetramethylethylenediamine, RNase A (from bovine pancreas) 
and bromophenol blue were obtained from Sigma Life Science (UK). Complete™ ULTRA Tablets, glass vials 
Protease Inhibitor Cocktail and cOmplete™ His-Tag Purification Resin were from Roche (Germany). Acetic 
acid ≥ 99.0% (T) and skimmed milk powder were obtained from Fluka Analytical (Switzerland). Triton® X-100, 
sodium carbonate and ammonium persulfate were obtained from Sigma-Aldrich (Germany). HEPES and 
Brilliant Blue R were obtained from Sigma (UK). Sodium dodecyl sulphate was obtained from BDH Laboratory 
(UK). 30% Acrylamide/Bis Solution, 37.5:1, Precision Plus Protein™ Dual Xtra Standards, Precision Protein 
StrepTactin-HRP Conjugate and Clarity Western enhanced chemiluminescence (ECL) Substrates were obtained 
from Bio-Rad Laboratories (USA). Mouse Anti-Hepatitis B Virus Antibody, core antigen (ayw), clone 10E11 was 
from Merck Millipore (USA). HCL was obtained from Aeros Organic (Germany). Anti 6-His affinity purified 
antibody was obtained from Bethyl Laboratories Inc. (USA). SnakeSkin™ Dialysis Tubing, 10 K MWCO was 
from Thermo Scientific (USA). Escherichia Coli, BL21 (DE3) was obtained from Dr. Mitla Garcia Maya, Randall 
Division of Cell and Molecular Biophysics, King’s College London, UK. Plasmid pET-22b(+ )-WT-HBc-His6 
encoding C-terminally His tagged HBc protein (residues 1–183) Accession No. CAA59538 was obtained from 
Associate Professor Chiaki Ogino, Chemical and Science Engineering Department, Kobe University, Japan.
Methods
Expression, purification and assembly of WT-HBc particles.  For gene expression of WT-HBc pro-
tein, the plasmid for expression of WT-HBc (pET-22b(+ )-WT-HBc-His6); was transfected into E.coli BL21 
(DE3) strain. E. coli transfected WT-HBc was expressed, purified and assembled via the following methods:
Conventional method. E. coli transfected WT-HBc (15 μ l) was cultured in 10 ml of LB media in the presence 
of 100 μ g/ml ampicillin and grown at 37 °C for 16 h using an incubator shaker. The culture was then diluted 
with 500 ml of fresh LB media in the presence of 100 μ g/ml ampicillin and grown to OD600 0.7–0.8 at 37 °C. The 
culture was induced by adding isopropyl-β -thiogalactopyranoside (IPTG) to a final concentration of 0.1 mM at 
25 °C overnight. Cells were harvested at 4500 g, 4 °C for 15 min. Pelleted cells were re-suspended in the 30 ml 
of lysis buffer (50 mM Tris, 100 mM NaCl, 5 mM EDTA, 0.2% v/v Triton X-100, pH 8.0). The cells were lysed 
on ice by three cycles of probe sonication for 1 min each with 1 min intervals to avoid heating the material. The 
supernatant was removed by centrifugation at 18,500 g, 4 °C for 30 min. The core particles in the cell pellet were 
washed in 30 ml of lysis buffer and collected by centrifugation at 18,500 g, 4 °C for 30 min. The cell pellet contain-
ing WT-HBc particles was denatured in 40 ml of dissociation buffer (4 M urea, 200 mM NaCl, 50 mM sodium 
carbonate, 10 mM 2-mercaptoethanol, pH 9.5) by overnight incubation at 4 °C. Then, the pellet was discarded by 
centrifugation at 18,500 g, 4 °C for 30 min.
Soluble fraction containing contaminating proteins was separated from HBc particle proteins using 
Ni2+-chelate affinity chromatography. A column with 6 ml of cOmplete™ His-Tag Purification Resin was equil-
ibrated with 3-times bed-volume (18 ml) of dissociation buffer. The column was loaded with the protein probe 
and washed with 18 ml of dissociation buffer. Bound HBc particle proteins were eluted with 14 ml of elution buffer 
(4 M urea, 200 mM NaCl, 50 mM sodium carbonate, 10 mM 2-mercaptoethanol, 1 M imidazole, pH 9.5). The 
eluted material was collected in 1 ml fractions. The aliquots of each fraction were subjected to sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and stained with Coomassie Brilliant Blue (CBB) to 
analyse their purity.
Fractions containing the HBc protein were re-assembled to particles by the removal of the urea in assembly 
buffer (500 mM NaCl, 50 mM Tris, 0.5 mM EDTA, pH 7.0). Specifically, protein fractions were dialysed against 5 l 
of dialysis buffer using SnakeSkin™ Dialysis Tubing, 10 K MWCO at 4 °C for overnight. Assembled HBc particles 
were filtered using 0.44 μ m filter to remove any aggregates.
Improved method. E. coli transfected WT-HBc (15 μ l) was cultured in 10 ml of AIM-TB media (10 g/l tryptone, 
5 g/l yeast extract, 3.3 g/l (NH4)2SO4, 6.8 g/l KH2PO4, 7.1 g/l Na2HPO4, 0.5 g/l glucose, 2.0 g/l α -lactose, 0.15 g/l 
MgSO4) in the presence of 100 μ g/ml ampicillin and grown at 37 °C for 16 h using an incubator shaker. The culture 
was then diluted with 500 ml of fresh AIM-TB media in the presence of 100 μ g/ml ampicillin and grown at 25 °C 
for 72 h. Cells were harvested at 4500 g, 4 °C for 15 min. Pelleted cells were re-suspended in the 30 ml of lysis buffer 
(50 mM Tris, 100 mM NaCl, 5 mM EDTA, 0.2% v/v Triton X-100, 1x cOmplete™ protease inhibitor pH 8.0). The 
www.nature.com/scientificreports/
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cells were treated with RNase A at a final concentration of 5 μ g/ml at 4 °C overnight. The lysate was sonicated 
using a probe sonicator on ice by three cycles for 1 min each with 1 min intervals to avoid heating the material. 
The supernatant was removed by centrifugation at 18,500 g, 4 °C for 30 min. The core particles in the cell pellet 
were washed in 30 ml of lysis buffer and collected by centrifugation at 18,500 g, 4 °C for 30 min. The cell pellet con-
taining WT-HBc particles was denatured in 40 ml of dissociation buffer (8 M urea, 200 mM NaCl, 50 mM sodium 
carbonate, 10 mM 2-mercaptoethanol, pH 9.5) by overnight incubation at 4 °C. Then, the pellet was discarded by 
centrifugation at 18,500 g, 4 °C for 30 min.
The soluble fraction containing-contaminating proteins were separated from HBc particle proteins using 
Ni2+-chelate affinity chromatography. A column with 6 ml of cOmplete™ His-Tag Purification Resin was equil-
ibrated with 3-times bed-volume (18 ml) of dissociation buffer. The column was loaded with the protein probe 
and washed with 18 ml of dissociation buffer. Bound HBc particle proteins were eluted with 14 ml of elution 
buffer (2 M urea, 200 mM NaCl, 50 mM sodium carbonate, 10 mM 2-mercaptoethanol, 1 M imidazole, pH 9.5). 
The eluted material was collected in 1 ml fractions. The aliquots of each fraction were subjected to SDS-PAGE and 
stained with CBB to analyse their purity.
Fractions containing the HBc protein were re-assembled to particles by the removal of urea. Specifically, pro-
tein fractions were dialysed against 2 l of dialysis buffer 1 (0.5 M urea, 100 mM Tris, 150 mM NaCl, 2 mM DTT, 
1 mM EDTA, 10 mM CaCl2, pH 8.0) using SnakeSkin™ Dialysis Tubing, 10 K MWCO at 4 °C for 4 h, allowing 
HBc protein to start assembled. Then, the solution was dialysed against dialysis buffer 2 (100 mM Tris, 150 mM 
NaCl, 1 mM EDTA, 10 mM CaCl2, pH 8.0) to completely removed urea and DTT, hence assembled HBc particles. 
HBc particles were filtered using 0.44 μ m filter to remove any aggregates.
All protein concentrations were measured using NanoDrop™ ND-1000 UV-Vis Spectrophotometer.
Tapping mode Atomic Force Microscopy (TM-AFM) analysis of purified WT-HBc particles.  A 
10 μ g/ml sample of purified WT-HBc particles (100 μ l) was deposited on mica surfaces for 5 min and then flushed 
with air. TM-AFM on the mica substrates were carried out in air at 25 °C using a Bruker Dimension ICON 
with Scan Assist. The surfaces were imaged with a general purpose-tapping tip made by MikroMasch in Estonia 
(NSC15/no Al, tip radius < 10 nm; tip height = 20–25 μ m; cone angle < 40°; cantilever thickness = 3.5–4.5 μm; 
cantilever width = 32–28 μ m; cantilever length = 120–130 μ m; frequency f0 = 265–400 kHz; force constant 
k = 20–75 N m−1, VEECO, USA). The statistical analysis of the AFM images was carried out using WSxM v5.0 
Developed 6.2 software (Spain).
SDS-PAGE and western blot analysis of WT-HBc particles.  The expression of each WT-HBc mon-
omer was confirmed by western blotting. The purified WT-HBc particles were analysed by SDS-PAGE and 
electro-transferred onto a nitrocellulose membrane. For the detection of the His6-tag, rabbit anti-6-His antibody 
was used as a primary antibody at 1:1000 dilution followed by HRP-linked anti-rabbit at 1:1000 dilution. For 
the detection of the HBc, mouse anti-HBc antibody was used as a primary antibody at 1:1000 dilution, followed 
by HRP-linked anti-mouse at 1:1000 dilution. For staining of the ladder, Precision Protein StrepTactin-HRP 
Conjugate was used at 1:10,000 dilution. The specific bands were detected with enhanced chemiluminescence 
(ECL) detection system. The membrane was imaged using the ChemiDocTMMP and analysed with Image Lab 
4.1 software.
Circular Dichroism (CD) for protein secondary structure analysis. CD thermal scan measurements 
were performed on a Chirascan spectrometer (Applied Photophysics, Leatherhead, UK) supplied with a thermoe-
lectric temperature control system. Temperature-dependent conformational changes were measured for WT-HBc 
particles (0.1 mg/ml) in Tris buffer (5 mM, pH 8.0). CD spectra of the samples were recorded from 260 to 180 nm 
using a 0.5 mm cuvette at 6 °C before starting the thermal scan. The temperature sensitivity was then tested by 
increasing the temperature from 6 to 94 °C at 1 °C/min heating rate and 2 °C/step. At the end of the thermal scan, 
the sample was equilibrated at 94 °C and the CD spectrum was recorded. Once the thermal scan was completed, 
the samples were cooled to 6 °C and equilibrated for 15 min before recording the CD spectra. Data analysis was 
performed using Applied Photophysics Chirascan software, and the transition temperatures were determined 
with Global 3 analysis software for dynamic multimode spectroscopy.
Statistics. For all experiments, data were presented as mean ± SD, where n denotes the number of repeats. 
Independent variable Student t tests were performed using one-way ANOVA. The t-value, degrees of freedom and 
two-tailed significance (p-value) were determined. *p < 0.05, **p < 0.01 and ***p < 0.001.
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